MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Xenomics, Inc. (PINKSHEETS: XNOM), a developer of medical DNA diagnostic technologies, provided an update on its commercial activities regarding NPM1 testing for Acute Myeloid Leukemia (AML). In 2008, the Company granted nonexclusive license rights to Laboratory Corporation of America® Holdings (LabCorp®) and to InVivoScribe Technologies to offer mutation analysis of NPM1 as a laboratory service for the diagnosis, stratification and monitoring of patients with AML. The agreements include up-front payments, royalties, and milestone payments to Xenomics and do not encompass tests that may be developed by the Company based on its proprietary Transrenal nucleic acid technology. Xenomics had previously announced that it granted Warnex Medical Laboratories, a division of Warnex Inc., similar nonexclusive rights to NPM1 in Canada.
